Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06980480 · ClinicalTrials.gov registry record · Phase 3
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
A Phase 3 study of Multiple Myeloma and Secondary Immunodeficiency, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 183
- Enrollment target
- 16
- Study locations
NCT06980480 is a Phase 3 study of Multiple Myeloma and Secondary Immunodeficiency that is actively recruiting participants, run by Takeda. The registered enrollment target is 183 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (66% lower). The trial reports 16 study locations across 12 states.
The verdict
NCT06980480, a Phase 3 study of Multiple Myeloma and Secondary Immunodeficiency, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 183 participants
- Enrollment target
- 16
- Study locations
Study Summary
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x cluster of differentiation 3 (CD3) directed bispecific antibody therapy. Participants will be randomly assigned to one of two groups: 1. Primary infection prevention group: They will receive IGI, 10% for 12 months. 2. Secondary infection prevention group: They will only receive IGI, 10% if they develop a serious infection during the 12 months study period. During the study, participants will visit their study clinic 15 times (for 4-week dosing interval) or 19 times (for 3-week dosing interval) and their total participation duration will be up to 14 months (including screening period of up to 8 weeks).
Conditions Studied
Interventions
- BIOLOGICAL IGI, 10%
Study Locations (16)
Other
- Universitaetsklinikum St. Poelten - Sankt Pölten
- Krankenhaus der Barmherzigen Schwestern Wien - Vienna
- St. Antonius Ziekenhuis - Nieuwegein
- Aidport sp. z o.o. - Skorzewo
- County Hospital (Stafford Hospital) - Stafford
Alabama
- Infirmary Health - Diagnostic & Medical Clinic (DMC) - Mobile
California
- Chao Family Comprehensive Cancer Center UCI - Orange
Kansas
- University of Kansas - Westwood
Maryland
- University of Maryland | Greenebaum Cancer Center - Baltimore
Michigan
- Henry Ford Health System - Detroit
Missouri
- Washington University School of Medicine - St Louis
New York
- New York Oncology Hematology - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2028-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06980480
The ClinicalTrials.gov registry entry for NCT06980480 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (66% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which IGI, 10% is the first listed.
NCT06980480 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06980480 about?
NCT06980480 is a clinical study titled "A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma". Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x clus...
What is the current status of trial NCT06980480?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 183 participants. The study started on 2026-01-14. Estimated completion is 2028-09-11.
What conditions does trial NCT06980480 study?
This clinical trial studies the following conditions: Multiple Myeloma, Secondary Immunodeficiency.
What interventions are being tested in trial NCT06980480?
The interventions under investigation include: IGI, 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT06980480?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06980480 being conducted?
This trial has 16 study locations across Alabama, California, Kansas, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.